New Delhi, September 3, 2024 — In a significant regulatory move, the Indian government has announced a ban on 156 combination drugs, including widely used medications such as paracetamol and cetirizine. This decision comes after a thorough review by the Drugs Technical Advisory Board (DTAB), which found that the banned drugs lack therapeutic justification and may pose risks to human health.
The combination drugs affected by this ban were commonly used for the treatment of fever, cold, and allergies. These medications, which often combined paracetamol with other active ingredients, were popular for their convenience and effectiveness in addressing multiple symptoms simultaneously. Cetirizine, an antihistamine used to relieve allergy symptoms, was also part of the banned combinations.
The DTAB’s review concluded that there is no valid therapeutic reason for the combination of these ingredients, raising concerns about potential health risks associated with their use. The advisory board emphasized that the drugs might not provide the intended benefits and could lead to adverse effects.
In addition to the ban on combination drugs, the Indian government is also reviewing the use of 34 multivitamin products. This review aims to assess the safety and efficacy of these supplements and ensure that they meet appropriate health standards. The move underscores the government’s commitment to safeguarding public health and ensuring that all medications and supplements available in the market are both safe and effective.
The ban on these drugs reflects a growing trend toward more stringent regulation of pharmaceuticals in India. It is part of a broader effort to improve drug safety and ensure that only those medications with proven therapeutic benefits are available to consumers.
The pharmaceutical industry and healthcare professionals are urged to stay informed about these regulatory changes and to consider alternative treatments that comply with the new guidelines. The government has also announced plans to work closely with drug manufacturers to address any issues arising from this ban and to facilitate the transition to safer and more effective medications.
As the review process continues, patients and healthcare providers are advised to consult with medical professionals before making any changes to their treatment regimens. The Indian government remains committed to ensuring the highest standards of health and safety for its citizens.